VEGFR2

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

Retrieved on: 
Friday, December 2, 2022

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis. The final analysis is expected to be reached in mid-2023.

Key Points: 
  • "We remain committed to developing our portfolio of oncology candidates and advancing our lung cancer strategy to positively impact the lives of patients with cancer.
  • Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12Dinhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.
  • For more information about Mirati Therapeutics, Inc., visit us at Mirati.com or follow us on Twitter and LinkedIn .
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial

Retrieved on: 
Thursday, May 26, 2022

SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced its Phase 2 clinical trial (Study RM-202) evaluating rivoceranib, an orally administered tyrosine kinase inhibitor (TKI), demonstrated clinical effectiveness in patients with progressive recurrent or metastatic adenoid cystic carcinoma (R/M ACC). Elevar will present topline findings at the American Society of Clinical Oncology (ASCO)’s annual meeting on June 6.

Key Points: 
  • Elevar will present topline findings at the American Society of Clinical Oncology (ASCO)s annual meeting on June 6.
  • It is also gratifying that rivoceranib demonstrates a favorable safety profile, reflecting adverse events consistent with other VEGFR TKIs.
  • Rivoceranib, co-developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (JHP) in China and Elevar Therapeutics globally, with the exception of China.
  • Orphan drug designations have been granted in gastric cancer (U.S., EU and South Korea), adenoid cystic carcinoma (U.S.) and hepatocellular carcinoma (U.S.).

Ranibizumab Biosimilars Market Research 2022: Comprehensive Insights About 17+ Companies and 17+ Marketed and Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 14, 2022

The publisher's, "Ranibizumab Biosimilars - Pipeline Insight, 2022," report provides comprehensive insights about 17+ companies and 17+ marketed and pipeline drugs in Ranibizumab Biosimilars pipeline landscape.

Key Points: 
  • The publisher's, "Ranibizumab Biosimilars - Pipeline Insight, 2022," report provides comprehensive insights about 17+ companies and 17+ marketed and pipeline drugs in Ranibizumab Biosimilars pipeline landscape.
  • A detailed picture of the Ranibizumab Biosimilars pipeline landscape is provided which includes the disease overview and Ranibizumab Biosimilars treatment guidelines.
  • The assessment part of the report embraces, in depth Ranibizumab Biosimilars commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Ranibizumab Biosimilars R&D.

AXL Kinase Inhibitor Pipeline Market Report 2022: Insights on 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022

This "AXL Kinase Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape.

Key Points: 
  • This "AXL Kinase Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape.
  • AXL receptor tyrosine Kinase is a member of the tyrosine-protein Kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein Kinase Mer family of receptor tyrosine Kinases.
  • This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their AXL Kinase Inhibitor drug candidates in the most advanced stage, i.e.

AsclepiX appoints Dr. Amir Shojaei as Chief Scientific Officer and Executive Vice President, Clinical Development

Retrieved on: 
Friday, October 8, 2021

Amir has built a career in life sciences as a leader with over two and a half decades of drug development experience, focused on the clinical development, registration and commercialization of biopharmaceuticals and biologics in multiple therapeutic areas.

Key Points: 
  • Amir has built a career in life sciences as a leader with over two and a half decades of drug development experience, focused on the clinical development, registration and commercialization of biopharmaceuticals and biologics in multiple therapeutic areas.
  • AsclepiX has identified numerous families of peptides that act as integrin regulators such as that in AXT107 (gersizangitide) with the potential to treat retinal diseases.
  • Im honored to be working with the AsclepiX team as we progress through phase 1/2a clinical studies in nAMD and DME and in expanding our development pipeline in ophthalmology and beyond.
  • Prior to joining, Dr. Shojaei served as the CEO for TherOptix and Chief Development Officer overseeing clinical development and regulatory affairs at TearClear.

Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers

Retrieved on: 
Wednesday, August 25, 2021

We are thankful to the investigators and patients, without whom our research would not be possible."

Key Points: 
  • We are thankful to the investigators and patients, without whom our research would not be possible."
  • Studies of adagrasib have shown that the drug has a long half-life, extensive tissue distribution and is well tolerated.
  • Adagrasib has also shown single-agent responses in non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and other solid tumors with KRASG12C mutations.
  • Adagrasib is a being evaluated in several clinical trials in combination with other anti-cancer therapies with strong scientific rationale in patients with advanced solid tumors.